U.S. Legislation & Regulation
Enabling clinical research by advancing U.S. legislation and regulation
ACRO supports a strong, robust FDA with expanded resources to ensure better control over the quality, safety, and efficacy of clinical trials and drug development in the United States.
ACRO’s U.S. agenda is focused on promoting policies that foster innovation. ACRO engages with – and provides industry expertise to – the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the U.S. Congress, and other government bodies.
In 2024, ACRO members employed roughly 125,000 individuals in the U.S. in more than 20 states.
Contact us for more information about our U.S. advocacy.
ACRO’s US Regulatory & Legislative Comments
Filter Results:
Statement for the Record
ACRO Statement for the Record submitted to the Senate Appropriations Committee hearing on Biomedical Research
Comment Letter